Biopharmaceutical company ARCA biopharma announced it has expanded its clinical trial leadership team with the addition of three new hires in the areas of clinical development and quality assurance.
The new employees are being hired for the positions of vice president, clinical development; senior director, quality; and senior clinical program manager. These three industry professionals, who have more than 45 collective years of clinical development and QA experience, will join current ARCA employees in overseeing the carrying out of GENETIC-AF, ARCA's Phase 2B/3 clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation.
Joining ARCA as its new vice president, clinical development is Christopher Dufton, Ph.D. Dufton who previously served as director of clinical research at Gilead Sciences. Prior to that, he was the associate director of clinical development of Myogen, Inc., where he served as a member of the development team responsible for the clinical program leading to the approval of Letairis (ambrisentan) for treating pulmonary arterial hypertension (PAH). Letairis has been approved for the treatment of PAH in the United States and Europe.
ARCA's new senior director, quality, Sharon Perry, served previously as director of quality assurance (QA) at Accera Pharma. She also brings additional relevant QA experience from her previous work at Gilead Sciences, PR Pharmaceuticals, and Pfizer.
Finally, Jennifer Merriweather joins ARCA as the company's new senior clinical program manager. Merriweather served previously as the clinical program manager at Gilead Sciences and also brings relevant clinical development experience from her work with Myogen, Inc.
ARCA biopharma is a biopharmaceutical company focused on developing genetically targeted therapies for cardiovascular diseases. Gencaro (bucindolol hydrochloride), the company's lead product candidate, is an investigational, pharmacologically unique beta-blocker and mild vasodilator that is being developed for atrial fibrillation. The company has identified common genetic variations it believes can predict individual patient response to Gencaro, which gives it the potential to be the first genetically targeted atrial fibrillation prevention treatment. ARCA has partnered with Medtronic, Inc. for the Phase 2B portion of the GENETIC-AF trial.
For more information, visit www.arcabiopharma.com
Please see disclaimer on the MissionIR website